PRJNA321420: Mapping heterogeneity in a patient-derived melanoma culture by single-cell RNA-seq

概要: Recent technological advances in single-cell genomics make it possible to analyze cellular heterogeneity of tumor samples. Here; we applied single-cell RNA-seq to measure the transcriptomes of 307 single cells cultured from three biopsies of three different patients with a BRAF/NRAS wild type; BRAF mutant/NRAS wild type and BRAF wild type/NRAS mutant melanoma metastasis; respectively. Analysis based on self-organizing maps identified sub-populations defined by multiple gene expression modules involved in proliferation; oxidative phosphorylation; pigmentation and cellular stroma. Gene expression modules had prognostic relevance when compared with gene expression data from published melanoma samples and patient survival data. We surveyed kinome expression patterns across sub-populations of the BRAF/NRAS wild type sample and found that CDK4 and CDK2 were consistently highly expressed in the majority of cells; suggesting that these kinases might be involved in melanoma progression. Treatment of cells with the CDK4 inhibitor palbociclib restricted cell proliferation to a similar; and in some cases greater; extent than MAPK inhibitors. Finally; we identified a low abundant sub-population in this sample that highly expressed a module containing ABC transporter ABCB5; surface markers CD271 and CD133; and multiple aldehyde dehydrogenases (ALDHs); as markers for melanoma stem or initiating cells. Patient-derived cultures of the BRAF mutant/NRAS wild type and BRAF wild type/NRAS mutant metastases showed more homogeneous single-cell gene expression patterns with gene expression modules for proliferation and ABC transporters. Taken together; our results describe an intertumor and intratumor heterogeneity in melanoma short-term cultures which might be relevant for patient survival; and suggest promising targets for new treatment approaches in melanoma therapy.

项目整体设计: RNA-seq of 307 single cells cultured from three biopsies of three different patients with a BRAF/NRAS wild type; BRAF mutant/NRAS wild type and BRAF wild type/NRAS mutant melanoma metastasis; respectively.